{"transactions":[{"id":1018415,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-10-15T11:58:45.000Z","date":"2025-10-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30002,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 9, 2025, pursuant to that certain Business Combination Agreement, dated July 13, 2025 (as amended by the Amendment Agreement, dated September 23, 2025, the \"Agreement\"), by and among the Issuer, XenoTherapeutics, Inc., Xeno Acquisition Corp. (\"Purchaser\") and XOMA Royalty Corporation, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) cash consideration of approximately US$0.12 per share and (ii) one contingent value right (\"CVR\") for each common share entitling its holder to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the transactions contemplated by the Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-099650","document":"tm2528208-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633932/000110465925099650/tm2528208-3_4seq1.xml","form_type":"4"}},{"id":1558409,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true}}],"security":"Options","published_at":"2024-03-28T12:38:05.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":9.04,"exercise_date":"2025-03-25","expiration_date":"2034-03-25","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950172-24-000138","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633932/000095017224000138/form4.xml","form_type":"4"}},{"id":1679099,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-01-16T13:41:27.000Z","date":"2023-11-06","kind":"other","planned":false,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects a transfer pursuant to a property settlement agreement."}],"balance_after":30002,"source":{"system":"sec-edgar","filing":"0001209191-24-001597","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1633932/000120919124001597/doc4.xml","form_type":"4"}},{"id":1679098,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-01-16T13:41:27.000Z","date":"2023-10-30","kind":"other","planned":false,"acquired":false,"shares":17502,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects a transfer pursuant to a property settlement agreement."}],"balance_after":42502,"source":{"system":"sec-edgar","filing":"0001209191-24-001597","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633932/000120919124001597/doc4.xml","form_type":"4"}},{"id":1833465,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-07-06T17:19:16.000Z","date":"2023-07-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":11786,"price":3.08,"value":36300.88,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units (\"RSUs\") were granted to the Reporting Person by the issuer under the Issuer's 2021 Stock Option and Incentive Plan on September 10, 2022. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. This transaction reflects the sufficient shares sold to pay applicable income taxes related to the 50% vesting on July 1, 2023."}],"balance_after":578403,"source":{"system":"sec-edgar","filing":"0001209191-23-041610","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664852/000120919123041610/doc4.xml","form_type":"4"}},{"id":2031995,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Appreciation Right","published_at":"2023-02-03T17:01:20.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":320000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Time Vested Stock Appreciation Right (\"TV SAR\") represents the right to receive either, (i) the largest whole number of shares of stock with a value closest to, but not in excess of, the product of the increase in fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TV SAR, multiplied by the number of shares of common stock underlying the TV SAR that is being exercised, or (ii) the Company may elect to make cash payment measured by the increase in the fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TVSAR. One-third of the TV SAR awards will vest on August 1, 2023 and the remaining two-thirds will vest on August 1, 2024. The TV SAR awards expire on February 1, 2033 and have an exercise price of $1.73 per share, the closing price of the common stock on the grant date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Each Time Vested Stock Appreciation Right (\"TV SAR\") represents the right to receive either, (i) the largest whole number of shares of stock with a value closest to, but not in excess of, the product of the increase in fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TV SAR, multiplied by the number of shares of common stock underlying the TV SAR that is being exercised, or (ii) the Company may elect to make cash payment measured by the increase in the fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TVSAR. One-third of the TV SAR awards will vest on August 1, 2023 and the remaining two-thirds will vest on August 1, 2024. The TV SAR awards expire on February 1, 2033 and have an exercise price of $1.73 per share, the closing price of the common stock on the grant date."}],"balance_after":320000,"derivative":{"exercise_price":1.73,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":320000},"source":{"system":"sec-edgar","filing":"0001209191-23-006998","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1664852/000120919123006998/doc4.xml","form_type":"4"}},{"id":2031994,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T17:01:20.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":320000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option shall vest as follows: one-third on August 1, 2023 and the remaining two-thirds on August 1, 2024."}],"balance_after":320000,"derivative":{"exercise_price":1.73,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":320000},"source":{"system":"sec-edgar","filing":"0001209191-23-006998","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1664852/000120919123006998/doc4.xml","form_type":"4"}},{"id":2031993,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-03T17:01:20.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":4,"price":0.867,"value":3.468,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by the reporting individual under the issuer's 2021 Employee Stock Purchase Plan (\"ESPP\") in a transaction exempt under Rule 16b-3(c)."}],"balance_after":590193,"source":{"system":"sec-edgar","filing":"0001209191-23-006998","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664852/000120919123006998/doc4.xml","form_type":"4"}},{"id":2128445,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-01T11:07:30.000Z","date":"2022-06-29","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the options vest after 12 months from the date of grant."}],"balance_after":22500,"derivative":{"exercise_price":3.6,"expiration_date":"2032-06-29","underlying":"Common Shares","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-22-054971","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633932/000120919122054971/doc4.xml","form_type":"4"}},{"id":2159880,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-09-13T16:30:40.000Z","date":"2022-09-10","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent restricted stock units (\"RSUs\") issued under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,509 shares previously acquired under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":590189,"source":{"system":"sec-edgar","filing":"0000899243-22-030931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664852/000089924322030931/doc4.xml","form_type":"4"}},{"id":2197144,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-08-02T17:02:32.000Z","date":"2022-07-29","kind":"purchase","acquired":true,"shares":39382,"price":4.25,"value":167373.5,"ownership":{"direct":true},"balance_after":508680,"source":{"system":"sec-edgar","filing":"0000899243-22-027404","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664852/000089924322027404/doc4.xml","form_type":"4"}},{"id":2200722,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-28T19:52:49.000Z","date":"2022-07-28","kind":"purchase","acquired":true,"shares":3090,"price":4.25,"value":13132.5,"ownership":{"direct":true},"balance_after":469298,"source":{"system":"sec-edgar","filing":"0000899243-22-026986","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1664852/000089924322026986/doc4.xml","form_type":"4"}},{"id":2200721,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-28T19:52:49.000Z","date":"2022-07-26","kind":"purchase","acquired":true,"shares":5528,"price":4.24,"value":23438.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.18 to $4.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":466208,"source":{"system":"sec-edgar","filing":"0000899243-22-026986","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664852/000089924322026986/doc4.xml","form_type":"4"}},{"id":2201683,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-26T19:38:03.000Z","date":"2022-07-22","kind":"purchase","acquired":true,"shares":9444,"price":3.7497,"value":35412.1668,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.735 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":460680,"source":{"system":"sec-edgar","filing":"0000899243-22-026759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664852/000089924322026759/doc4.xml","form_type":"4"}},{"id":2415765,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-02T18:01:43.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option shall vest as follows: 25% shall vest on February 1, 2023; and the remaining shall vest in 36 equal monthly installments thereafter."}],"balance_after":500000,"derivative":{"exercise_price":9.1,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000899243-22-004202","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1664852/000089924322004202/doc4.xml","form_type":"4"}},{"id":2415764,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-02T18:01:43.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":1470,"price":13,"value":19110.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by the reporting individual under the issuer's 2021 Employee Stock Purchase Plan (\"ESPP\") in a transaction exempt under Rule 16b-3(c)."}],"balance_after":451236,"source":{"system":"sec-edgar","filing":"0000899243-22-004202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664852/000089924322004202/doc4.xml","form_type":"4"}},{"id":2895170,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-26T19:02:45.000Z","date":"2020-12-11","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting terms have been amended such that 100% of the options vest after 12 months from the date of grant."}],"balance_after":16500,"derivative":{"exercise_price":7,"expiration_date":"2030-12-11","underlying":"Common Shares","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001209191-21-005512","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633932/000120919121005512/doc4a.xml","form_type":"4/A","original_submission_date":"2021-01-11"}},{"id":2910987,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-11T16:45:38.000Z","date":"2020-12-11","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options vest after 12 months from the date of grant, and the remaining 75% vest in 36 equal installments with the first installment vesting at the end of the 13th month and subsequent installments vesting on every one month anniversary thereafter."}],"balance_after":16500,"derivative":{"exercise_price":7,"expiration_date":"2030-12-11","underlying":"Common Shares","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001209191-21-002952","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633932/000120919121002952/doc4.xml","form_type":"4"}},{"id":3678884,"issuer":{"id":111039,"kind":"organization","name":"VBI Vaccines Inc/BC","symbol":"VBIV"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy Common Shares)","published_at":"2019-02-04T17:13:13.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person is a participant in the Issuer's Incentive Plan (the \"Plan\"). The board of directors of the Issuer approved the option grant on January 31, 2019 (the \"Grant Date\"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 31, 2019 (the \"Option Agreement\"). The options vest and become exercisable in 36 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement."}],"balance_after":200000,"derivative":{"exercise_price":1.67,"expiration_date":"2029-01-31","underlying":"Common Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-19-001335","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/764195/000149315219001335/ownership.xml","form_type":"4"}},{"id":3801178,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche B Convertible Preferred Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":8552024,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":412583},"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801177,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche A Convertible Preferred Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":6702213,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":323341},"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801176,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":7500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":361829},"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801175,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"purchase","acquired":true,"shares":453395,"price":15,"value":6800925.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":1623405,"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801174,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":412583,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number includes an aggregate of 72,257 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":1170010,"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801173,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":323341,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":685170,"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801172,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":361829,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":361829,"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3878867,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":1922682,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1922682},"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878866,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":755780,"ownership":{"direct":false,"nature":"See foonote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":755780},"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878865,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":938489,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":938489},"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878864,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"purchase","acquired":true,"shares":200000,"price":16,"value":3200000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":3816951,"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878863,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":1922682,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":3616951,"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878862,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":755780,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":1694269,"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878861,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":938489,"ownership":{"direct":false,"nature":"See foonote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":938489,"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3883789,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-06-25T18:18:34.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":2805179,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. (\"GPLP\"). Clarus Ventures III, LLC, (\"LLC\") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":678891},"source":{"system":"sec-edgar","filing":"0000899243-18-017968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1664852/000089924318017968/doc4.xml","form_type":"4"}},{"id":3883788,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-06-25T18:18:34.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":9435150,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. (\"GPLP\"). Clarus Ventures III, LLC, (\"LLC\") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2283434},"source":{"system":"sec-edgar","filing":"0000899243-18-017968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1664852/000089924318017968/doc4.xml","form_type":"4"}},{"id":3883787,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-25T18:18:34.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":678891,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. (\"GPLP\"). Clarus Ventures III, LLC, (\"LLC\") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any."}],"balance_after":2962325,"source":{"system":"sec-edgar","filing":"0000899243-18-017968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1664852/000089924318017968/doc4.xml","form_type":"4"}},{"id":3883786,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-25T18:18:34.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":2283434,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the total number of shares of Common Stock received by Clarus Lifesciences III, L.P. (\"Clarus\")  upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. (\"GPLP\"). Clarus Ventures III, LLC, (\"LLC\") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any."}],"balance_after":2283434,"source":{"system":"sec-edgar","filing":"0000899243-18-017968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664852/000089924318017968/doc4.xml","form_type":"4"}},{"id":3891831,"issuer":{"id":111039,"kind":"organization","name":"VBI Vaccines Inc/BC","symbol":"VBIV"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units (RSUs)","published_at":"2018-06-18T10:51:20.000Z","date":"2018-06-14","kind":"exercise","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest 1/3 per year annually over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest 1/3 per year annually over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date."}],"balance_after":12500,"derivative":{"underlying":"Common Shares","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001493152-18-008820","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/764195/000149315218008820/form4.xml","form_type":"4"}},{"id":3891830,"issuer":{"id":111039,"kind":"organization","name":"VBI Vaccines Inc/BC","symbol":"VBIV"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, no par value per share","published_at":"2018-06-18T10:51:20.000Z","date":"2018-06-14","kind":"exercise","acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date."}],"balance_after":37500,"source":{"system":"sec-edgar","filing":"0001493152-18-008820","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/764195/000149315218008820/form4.xml","form_type":"4"}},{"id":4090481,"issuer":{"id":111039,"kind":"organization","name":"VBI Vaccines Inc/BC","symbol":"VBIV"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy Common Shares)","published_at":"2018-01-25T14:51:42.000Z","date":"2018-01-23","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person is a participant in the Issuer's Incentive Plan (the \"Plan\"). The board of directors of the Issuer approved the option grant on January 23, 2018 (the \"Grant Date\"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 23, 2018 (the \"Option Agreement\"). The options vest and become exercisable in 36 equal monthly installments beginning on the first day of the month following the Grant Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement."}],"balance_after":75000,"derivative":{"exercise_price":4.19,"expiration_date":"2028-01-23","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001493152-18-001034","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/764195/000149315218001034/form4.xml","form_type":"4"}},{"id":4280134,"issuer":{"id":111039,"kind":"organization","name":"VBI Vaccines Inc/BC","symbol":"VBIV"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units (RSUs)","published_at":"2017-06-16T17:59:16.000Z","date":"2017-06-14","kind":"exercise","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest 1/3 per year over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date."}],"balance_after":25000,"derivative":{"expiration_date":"2026-06-14","underlying":"Common Shares","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001493152-17-006780","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/764195/000149315217006780/form4.xml","form_type":"4"}},{"id":4280133,"issuer":{"id":111039,"kind":"organization","name":"VBI Vaccines Inc/BC","symbol":"VBIV"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, no par value per share","published_at":"2017-06-16T17:59:16.000Z","date":"2017-06-14","kind":"exercise","acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001493152-17-006780","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/764195/000149315217006780/form4.xml","form_type":"4"}},{"id":4364066,"issuer":{"id":111039,"kind":"organization","name":"VBI Vaccines Inc/BC","symbol":"VBIV"},"owners":[{"id":74247,"kind":"person","name":"Requadt Scott","position":1,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy Common Shares)","published_at":"2017-04-04T18:24:41.000Z","date":"2017-03-31","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person is a participant in the Issuer's Incentive Plan (the \"Plan\"). The board of directors of the Issuer approvedthe option grant on January 26, 2017 (the \"Grant Date\"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated March 31, 2017 (the \"Option Agreement\"). The options vest and become exercisable in 48 equal monthly installments beginning on the first day of the month following the Grant Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement."}],"balance_after":12500,"derivative":{"exercise_price":3.79,"expiration_date":"2027-01-26","underlying":"Common Shares","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001493152-17-003498","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/764195/000149315217003498/form4.xml","form_type":"4"}}]}